We indeed found that the pan-PDE4 inhibitor rolipram elicited more profound effects on suppressing AAA than SMC-specific PDE4D deficiency (aortic diameters, 1.936 ± 0.203 mm vs. 1.425 ± 0.192 mm). Here, PDE4D is linked to triple-A syndrome.